Australia markets closed

Viridian Therapeutics, Inc. (1S1.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
11.20+0.10 (+0.90%)
As of 08:00AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 723.83M
Enterprise value 358.43M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.05k
Price/book (mrq)1.99
Enterprise value/revenue 1.34k
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.06
52-week change 3-54.13%
S&P500 52-week change 325.22%
52-week high 324.20
52-week low 310.20
50-day moving average 312.47
200-day moving average 315.05

Share statistics

Avg vol (3-month) 312
Avg vol (10-day) 315
Shares outstanding 563.82M
Implied shares outstanding 665.21M
Float 847.76M
% held by insiders 10.01%
% held by institutions 1111.99%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 313 Nov 2020

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-77,634.72%

Management effectiveness

Return on assets (ttm)-29.24%
Return on equity (ttm)-46.75%

Income statement

Revenue (ttm)288k
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)-26.50%
Gross profit (ttm)N/A
EBITDA -237.31M
Net income avi to common (ttm)-218.12M
Diluted EPS (ttm)-4.18
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)613.19M
Total cash per share (mrq)9.61
Total debt (mrq)21.96M
Total debt/equity (mrq)3.77%
Current ratio (mrq)23.99
Book value per share (mrq)6.00

Cash flow statement

Operating cash flow (ttm)-167.42M
Levered free cash flow (ttm)-94.11M